Nkarta (NasdaqGS:NKTX) FY Conference Summary Company Overview - Nkarta is an autoimmune company focused on discovering and developing natural killer (NK) cells for therapeutic use. [7] - The company is currently conducting two clinical trials: Ntrust-1 and Ntrust-2. [7] - **Ntrust-1**: Targets CD19 with allogeneic off-the-shelf NK cells in lupus nephritis. - **Ntrust-2**: A basket study targeting the same NK cell therapy in scleroderma, myositis, and vasculitis. [7] Clinical Trials and Development - Nkarta aims to provide updates on the data from both studies by mid-2026, focusing on proof of concept for advancing to pivotal trials. [7][8] - The company has initiated dose escalation in its trials, moving from an initial dose of 1 billion cells to 2 billion cells, with plans to escalate to 4 billion cells per dose. [17][19] - The total planned dosing for the next level is 12 billion cells across multiple administrations. [23] Advantages of NK Cell Therapy - NK cells are readily accessible and do not require apheresis, allowing for outpatient administration. [10] - The therapy has shown no cytokine release syndrome or neurotoxicity in treated patients, making it safer compared to other therapies. [10] - The short-lived effect of NK cells is considered beneficial for autoimmune diseases, allowing for immediate B-cell depletion. [10] Dosing Regimen - The dosing regimen includes lymphodepletion using fludarabine and cyclophosphamide, followed by NK cell administration on days 0, 3, and 7. [30] - The company has shifted from using cyclophosphamide alone to a combination with fludarabine to achieve complete B-cell depletion. [44][55] Market Position and Competition - Nkarta is aware of other companies exploring reduced lymphodepletion regimens but emphasizes the importance of complete B-cell depletion for durability of response. [55][60] - The company is monitoring competitors and their approaches, particularly in the context of NK cell therapies. [112] Financial Position - As of the end of Q3 2025, Nkarta reported approximately $316 million in cash, providing a runway until 2029. [170] - The company is not in immediate need of financing and is focused on executing its clinical programs. [172] Future Outlook - Nkarta plans to provide updates on both clinical trials and regulatory interactions throughout 2026. [172] - The company aims to target rheumatology medical meetings for data updates. [166] Biomarkers and Efficacy Tracking - Efficacy tracking will depend on the indication, with specific biomarkers being used for lupus nephritis and systemic sclerosis. [295] - The company intends to validate various biomarkers as it progresses in clinical development. [299] Conclusion - Nkarta is positioned to advance its NK cell therapies for autoimmune diseases, with a strong focus on safety, accessibility, and efficacy. The company is preparing for significant data releases in 2026 while maintaining a solid financial foundation. [170][172]